Search

Your search keyword '"Siegel, Jennifer J."' showing total 148 results
Start Over Author "Siegel, Jennifer J."
148 results on '"Siegel, Jennifer J."'

1. Integrating the 40-Gene Expression Profile (40-GEP) Test Improves Metastatic Risk-Stratification Within Clinically Relevant Subgroups of High-Risk Cutaneous Squamous Cell Carcinoma (cSCC) Patients

Author

Wysong, Ashley, Somani, Ally‐Khan, Ibrahim, Sherrif F., Cañueto, Javier, Fitzgerald, Alison L., Siegel, Jennifer J., Prasai, Anesh, Goldberg, Matthew S., Farberg, Aaron S., Regula, Christie, Bar, Anna, Kasprzak, Julia, Brodland, David G., Koyfman, Shlomo A., and Arron, Sarah T.

Published
2024
Full Text
View/download PDF

3. The Tissue Systems Pathology Test Outperforms Pathology Review in Risk Stratifying Patients With Low-Grade Dysplasia

Author

Goldblum, John, Montgomery, Elizabeth, Davison, Jon, Singh, Jagjit, Szymanski, Jared, Perry, Anthony, Seldenrijk, Kees, Kate, Fiebo ten, Offerhaus, G. Johan A., Drillenberg, Paul, Jansen, Casper, Leeuwis-Fedorovic, Natalja, Chetty, Runjan, Feakins, Roger, Jansen, Marnix, Chinyama, Catherine, Cooper, Edwin, Vaziri, Reza, Baretton, Gustavo, Tannapfel, Andrea, Vieth, Michael, Melcher, Balint, Mesteri, Ildiko, Müller, Heiko, Wetzel, Philipp, de Hertogh, Gert, Hoorens, Anne, Verschuere, Stepanie, Tamsin, An, Wetzels, Kevin, Caillie, Marie-Astrid van, Khoshiwal, Amir M., Frei, Nicola F., Pouw, Roos E., Smolko, Christian, Arora, Meenakshi, Siegel, Jennifer J., Duits, Lucas C., Critchley-Thorne, Rebecca J., and Bergman, Jacques J.G.H.M.

Published
2023
Full Text
View/download PDF

7. S599 The Tissue Systems Pathology Test Predicts Risk of Progression in Medicare-Eligible Patients with Barrett’s Esophagus

Author

Khara, Harshit S., primary, Davison, Jon M., additional, Goldblum, John, additional, Thota, Prashanthi N., additional, Duits, Lucas C., additional, Khoshiwal, Amir, additional, Bergman, Jacques J., additional, Falk, Gary, additional, Smolko, Christian, additional, Hall, Mary, additional, Siegel, Jennifer J., additional, Critchley-Thorne, Rebecca J., additional, and Diehl, David L., additional

Published
2023
Full Text
View/download PDF

9. 31-Gene Expression Profile Testing in Cutaneous Melanoma and Survival Outcomes in a Population-Based Analysis: A SEER Collaboration

Author

Bailey, Christine N., primary, Martin, Brian J., additional, Petkov, Valentina I., additional, Schussler, Nicola C., additional, Stevens, Jennifer L., additional, Bentler, Suzanne, additional, Cress, Rosemary D., additional, Doherty, Jennifer A., additional, Durbin, Eric B., additional, Gomez, Scarlett L., additional, Gonsalves, Lou, additional, Hernandez, Brenda Y., additional, Liu, Lihua, additional, Morawski, Bożena M., additional, Schymura, Maria J., additional, Schwartz, Stephen M., additional, Ward, Kevin C., additional, Wiggins, Charles, additional, Wu, Xiao-Cheng, additional, Goldberg, Matthew S., additional, Siegel, Jennifer J., additional, Cook, Robert W., additional, Covington, Kyle R., additional, and Kurley, Sarah J., additional

Published
2023
Full Text
View/download PDF

19. Real-World Evidence Shows Clinicians Appropriately Use the Prognostic 40-Gene Expression Profile (40-GEP) Test for High-Risk Cutaneous Squamous Cell Carcinoma (cSCC) Patients

Author

Hooper, Perry B., primary, Farberg, Aaron S., additional, Fitzgerald, Alison L., additional, Siegel, Jennifer J., additional, Rackley, Briana B., additional, Prasai, Anesh, additional, Kurley, Sarah J., additional, Goldberg, Matthew S., additional, and Litchman, Graham H., additional

Published
2022
Full Text
View/download PDF

23. Enhanced metastatic risk assessment in cutaneous squamous cell carcinoma with the 40-gene expression profile test

Author

Ibrahim, Sherrif F, primary, Kasprzak, Julia M, additional, Hall, Mary A, additional, Fitzgerald, Alison L, additional, Siegel, Jennifer J, additional, Kurley, Sarah J, additional, Covington, Kyle R, additional, Goldberg, Matthew S, additional, Farberg, Aaron S, additional, Trotter, Shannon C, additional, Reed, Kenneth, additional, Brodland, David G, additional, Koyfman, Shlomo A, additional, Somani, Ally-Khan, additional, Arron, Sarah T, additional, and Wysong, Ashley, additional

Published
2022
Full Text
View/download PDF

25. Attitudes of patients with cutaneous melanoma toward prognostic testing using the 31‐gene expression profile test.

Author

Ahmed, Kelli, Siegel, Jennifer J., Morgan‐Linnell, Sonia K., and LiPira, Kyleigh

Subjects
*PATIENTS' attitudes, *PROGNOSTIC tests, *MELANOMA, *GENE expression profiling
Abstract

Objective: Although most patients diagnosed with early‐stage cutaneous melanoma (CM) have excellent outcomes, because of the large number diagnosed each year, many will experience recurrence or death. Prognostic testing for CM using the 31‐gene expression profile (31‐GEP) test can benefit patients by helping guide risk‐appropriate treatment and surveillance plans. We sought to evaluate patients' attitudes toward prognostic testing with the 31‐GEP and assess whether patients experience decision regret about having 31‐GEP testing. Methods: A 43‐question survey was distributed by the Melanoma Research Foundation in June–August 2021 to CM patients enrolled in their database. Patients were asked questions regarding their decision to undergo 31‐GEP testing and the extent to which they experienced decision regret using a validated set of Decision Regret Scale questions. Results: We analyzed responses from patients diagnosed in 2014 or later (n = 120). Of these, 28 had received 31‐GEP testing. Most respondents (n = 108, 90%) desired prognostic information when diagnosed. Of those who received 31‐GEP testing, most felt the results were useful (n = 22 out of 24) and had regret scores significantly less than neutral regret, regardless of their test results (Class 1: p < 0.001; Class 2: p = 0.036). Further, decision regret scores were not significantly different between patients who received a Class 1 31‐GEP result and those who received a Class 2 result (mean Class 1 = 1.39 and mean Class 2 = 1.90, p = 0.058). Conclusions: Most newly diagnosed CM patients desired prognostic information about their tumors. Patients who received 31‐GEP testing felt it was useful and did not regret their decision to undergo 31‐GEP testing. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

30. The avian hippocampus, homing in pigeons and the memory representation of large-scale space

Author

Bingman, Verner P., Gagliardo, Anna, Hough, Gerald E., II, Ioale, Paolo, Kahn, Meghan C., and Siegel, Jennifer J.

Subjects
Homing pigeons -- Research, Homing pigeons -- Physiological aspects, Cognition in animals -- Research, Zoology and wildlife conservation
Abstract

The extraordinary navigational ability of homing pigeons provides a unique spatial cognitive system to investigate how the brain is able to represent past experiences as memory. In this paper, we first summarize a large body of lesion data in an attempt to characterize the role of the avian hippocampal formation (HF) in homing. What emerges from this analysis is the critical importance of HF for the learning of map-like, spatial representations of environmental stimuli used for navigation. We then explore some interesting properties of the homing pigeon HF, using for discussion the notion that the homing pigeon HF likely displays some anatomical or physiological specialization(s), compared to the laboratory rat, that account for its participation in homing and the representation of large-scale, environmental space. Discussed are the internal connectivity among HF subdivisions, the occurrence of neurogenesis, the presence of rhythmic theta activity and the electrophysiological profile of HF neurons. Comparing the characteristics of the homing pigeon HF with the hippocampus of the laboratory rat, two opposing perspectives can be supported. On the one hand, one could emphasize the subtle differences in the properties of the homing pigeon HF as possible departure points for exploring how the homing pigeon HF may be adapted for homing and the representation of large-scale space. Alternatively, one could emphasize the similarities with the rat hippocampus and suggest that, if homing pigeons represent space in a way different from rats, then the neural specializations that would account for the difference must lie outside HF. Only future research will determine which of these two perspectives offers a better approximation of the truth.

Published
2005

35. A clinical impact study of dermatologists' use of diagnostic gene expression profile testing to guide patient management

Author

Witkowski, Alexander, Jarell, Abel D, Ahmed, Kelli L, Siegel, Jennifer J, Russell, Brooke H, Rogers, Jason H, Goldberg, Matthew S, Fernandes, Neil F, Ludzik, Joanna, and Farberg, Aaron S

Abstract

Aim:Cutaneous melanocytic neoplasms with diagnostic and/or clinical ambiguity pose patient management challenges. Methods:Six randomized case scenarios with diagnostic/clinical uncertainty were described with/without a benign or malignant diagnostic gene expression profile (GEP) result. Results:Clinical impact was assessed by reporting the mean increase/decrease of management changes normalized to baseline (n = 32 dermatologists). Benign GEP results prompted clinicians to decrease surgical margins (84.2%). Malignant GEP results escalated surgical excision recommendations (100%). A majority (72.2%) reduced and nearly all (98.9%) increased follow-up frequency for benign or malignant GEP results, respectively. There was an overall increase in management plan confidence with GEP results. Conclusion:Diagnostic GEP tests help guide clinical decision-making in a variety of diagnostically ambiguous or clinicopathologically discordant scenarios.

Published
2024
Full Text
View/download PDF

37. The Tissue Systems Pathology Test Outperforms Pathology Review in Risk Stratifying Patients With Low-Grade Dysplasia.

Author

Khoshiwal, Amir M., Frei, Nicola F., Pouw, Roos E., Smolko, Christian, Arora, Meenakshi, Siegel, Jennifer J., Duits, Lucas C., Critchley-Thorne, Rebecca J., and Bergman, Jacques J.G.H.M.

Abstract

Low-grade dysplasia (LGD) is associated with an increased risk of progression in Barrett's esophagus (BE); however, the diagnosis of LGD is limited by substantial interobserver variability. Multiple studies have shown that an objective tissue systems pathology test (TissueCypher Barrett's Esophagus Test, TSP-9), can effectively predict neoplastic progression in patients with BE. This study aimed to compare the risk stratification performance of the TSP-9 test vs benchmarks of generalist and expert pathology. A blinded cohort study was conducted in the screening cohort of a randomized controlled trial of patients with BE with community-based LGD. Biopsies from the first endoscopy with LGD were assessed by the TSP-9 test and independently reviewed by 30 pathologists from 5 countries per standard practice. The accuracy of the test and the diagnoses in predicting high-grade dysplasia (HGD) and esophageal adenocarcinoma (EAC) were compared. A total of 154 patients with BE (122 men), mean age 60.9 ± 9.8 years were studied. Twenty-four patients progressed to HGD/EAC within 5 years (median time of 1.7 years) and 130 did not progress to HGD/EAC within 5 years (median 7.8 years follow-up). The TSP-9 test demonstrated higher sensitivity (71% vs mean 63%, range 33%–88% across 30 pathologists), than the pathology review in detecting patients who progressed (P =.01186). The TSP-9 test outperformed the pathologists in risk stratifying patients with BE with LGD. Care guided by the test can provide an effective solution to variable pathology review of LGD, improving health outcomes by upstaging care to therapeutic intervention for patients at high risk for progression, while reducing unnecessary interventions in low-risk patients. [Display omitted] A study in the screening cohort of a randomized controlled trial demonstrated that a tissue systems pathology test (TSP-9) objectively risk-stratified patients with Barrett's esophagus and community-based low-grade dysplasia, whereas a panel of expert and generalist pathologists demonstrated significant interobserver variability. The TSP-9 test outperformed pathology review in predicting neoplastic progression and detected 80.4% of progressors when used as an adjunct to pathology review of low-grade dysplasia. The results of the study indicate that the TSP-9 test provides an objective solution to subjective and variable pathology review and can improve outcomes for patients with an initial diagnosis of low-grade dysplasia by maximizing the identification and early treatment of progressors with eradication therapy and downstaging the management of low-risk patients to a surveillance-only approach. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

40. Ultraflexible nanoelectronic probes form reliable, glial scar–free neural integration

Author

Luan, Lan, primary, Wei, Xiaoling, additional, Zhao, Zhengtuo, additional, Siegel, Jennifer J., additional, Potnis, Ojas, additional, Tuppen, Catherine A, additional, Lin, Shengqing, additional, Kazmi, Shams, additional, Fowler, Robert A., additional, Holloway, Stewart, additional, Dunn, Andrew K., additional, Chitwood, Raymond A., additional, and Xie, Chong, additional

Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results